CLARITY PHARMACEUTICALS LTD - Announcements

2.97%

$4.50

Market Cap $1.699B

Healthcare Biotechnology

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical... Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. LATEST: Race Oncology Accelerates Game-Changing Cancer Drug.

Announcements

Filter Results

All Price Sensitive Only

CU6	Cleansing Notice		09:39	438.68KB	Share
CU6	Ceasing to be a substantial holder		31/07/25	417.54KB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/25	9.27MB	Share
CU6	Application for quotation of securities - CU6		31/07/25	14.08KB	Share
CU6	Becoming a substantial holder		29/07/25	769.01KB	Share
CU6	Proposed issue of securities - CU6		28/07/25	15.22KB	Share
CU6	Clarity successfully completes $203 million institutional pl	PRICE SENSITIVE	28/07/25	288.81KB	Share
CU6	Change in substantial holding		24/07/25	1.13MB	Share
CU6	Co-PSMA trial recruitment successfully completed	PRICE SENSITIVE	17/07/25	297.47KB	Share
CU6	Notification of cessation of securities - CU6		14/07/25	12.79KB	Share
CU6	Cleansing Notice		04/07/25	248.26KB	Share
CU6	Application for quotation of securities - CU6		04/07/25	15.55KB	Share
CU6	Notice of initial substantial holder		04/07/25	191.69KB	Share
CU6	Change of Director's Interest Notice - M Parker		04/07/25	256.82KB	Share
CU6	Change of Director's Interest Notice - C Biggin		04/07/25	256.88KB	Share
CU6	Change of Director's Interest Notice - A Taylor		04/07/25	257.11KB	Share
CU6	Cleansing Notice		02/07/25	594.79KB	Share
CU6	Application for quotation of securities - CU6		02/07/25	18.79KB	Share
CU6	Change in substantial holding		01/07/25	1.2MB	Share
CU6	Cleansing Notice		24/06/25	248.3KB	Share
CU6	Application for quotation of securities - CU6		24/06/25	18.09KB	Share
CU6	Clarity enters a Commercial Manufacturing Agreement	PRICE SENSITIVE	17/06/25	318.57KB	Share
CU6	SABRE topline results	PRICE SENSITIVE	13/06/25	392.88KB	Share
CU6	DISCO topline results	PRICE SENSITIVE	05/06/25	373.31KB	Share
CU6	Ceasing to be a substantial holder		05/06/25	250.34KB	Share
CU6	Notification regarding unquoted securities - CU6		30/05/25	15.85KB	Share
CU6	First patient imaged in Phase III AMPLIFY trial	PRICE SENSITIVE	29/05/25	328.2KB	Share
CU6	AMPLIFY trial commences	PRICE SENSITIVE	20/05/25	332.81KB	Share
CU6	Ceasing to be a substantial holder		15/05/25	441.44KB	Share
CU6	Becoming a substantial holder		13/05/25	384.07KB	Share
CU6	Change in substantial holding		02/05/25	1.45MB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	8.35MB	Share
CU6	Change in substantial holding		22/04/25	1.36MB	Share
CU6	Ceasing to be a substantial holder		17/04/25	489.99KB	Share
CU6	Clarity signs commercial-scale copper-64 Supply Agreement	PRICE SENSITIVE	17/04/25	241.42KB	Share
CU6	$11.1 million RDTI and refocus on high-priority programs	PRICE SENSITIVE	17/04/25	245.71KB	Share
CU6	Becoming a substantial holder		16/04/25	800.71KB	Share
CU6	First patient treated in the Phase II of the SECuRE trial	PRICE SENSITIVE	15/04/25	333.19KB	Share
CU6	Change of Registered Office and Registry Address		14/04/25	282.98KB	Share
CU6	Becoming a substantial holder		11/04/25	424.61KB	Share
CU6	Notification of cessation of securities - CU6		10/04/25	12.79KB	Share
CU6	Becoming a substantial holder		09/04/25	2.18MB	Share
CU6	Cleansing Notice		05/03/25	248.11KB	Share
CU6	Application for quotation of securities - CU6		05/03/25	17.62KB	Share
CU6	Clarity signs Cu-64 Supply Agreement with UQ	PRICE SENSITIVE	05/03/25	304.33KB	Share
CU6	SECuRE trial update	PRICE SENSITIVE	05/03/25	427.22KB	Share
CU6	Half Yearly Report and Accounts		28/02/25	14.28MB	Share
CU6	Appendix 4D	PRICE SENSITIVE	28/02/25	832.35KB	Share
CU6	Clarity receives US FDA FTD for the treatment of mCRPC	PRICE SENSITIVE	19/02/25	587.09KB	Share
CU6	Response to ASX Cleansing Notice Timing Letter		18/02/25	1.16MB	Share
CU6	Cleansing Notice		11/02/25	247.84KB	Share
CU6	Application for quotation of securities - CU6		11/02/25	22.79KB	Share
CU6	Clarity expands pipeline with Cu-64/67 SAR-trastuzumab	PRICE SENSITIVE	11/02/25	325.31KB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/25	9.75MB	Share
CU6	Cleansing Notice		29/01/25	170.38KB	Share
CU6	Application for quotation of securities - CU6		29/01/25	25.57KB	Share
CU6	Clarity to present COBRA and CLARIFY abstracts	PRICE SENSITIVE	28/01/25	337.19KB	Share
CU6	Clarity receives U.S. FDA Fast Track Designation	PRICE SENSITIVE	24/01/25	663.71KB	Share
CU6	Cleansing Notice		22/01/25	169.83KB	Share
CU6	Application for quotation of securities - CU6		22/01/25	17.71KB	Share
CU6	Notification of cessation of securities - CU6		08/01/25	14.16KB	Share
CU6	Cleansing Notice		18/12/24	222.15KB	Share
CU6	Application for quotation of securities - CU6		18/12/24	17.75KB	Share
CU6	Novel FAP-targeted radiopharmaceutical	PRICE SENSITIVE	18/12/24	186.57KB	Share
CU6	S&P DJI Announces December 2024 Quarterly Rebalance	PRICE SENSITIVE	06/12/24	81.25KB	Share
CU6	Cleansing Notice		06/12/24	595.39KB	Share
CU6	Application for quotation of securities - CU6		06/12/24	17.75KB	Share
CU6	Last patient assessment completed for SARTATE trial	PRICE SENSITIVE	28/11/24	438.4KB	Share
CU6	First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA	PRICE SENSITIVE	26/11/24	1.74MB	Share
CU6	Change of Director's Interests - All Directors		26/11/24	494.14KB	Share
CU6	Notification regarding unquoted securities - CU6		25/11/24	43.31KB	Share
CU6	Results of Meeting		20/11/24	70.52KB	Share
CU6	Chairperson Address AGM	PRICE SENSITIVE	20/11/24	220.88KB	Share
CU6	AGM MD Presentation	PRICE SENSITIVE	20/11/24	2.69MB	Share
CU6	Head-to-head IIT with SAR-bisPSMA	PRICE SENSITIVE	18/11/24	191.51KB	Share
CU6	Clarity and Nucleus RadioPharma sign MSA	PRICE SENSITIVE	11/11/24	212.65KB	Share
CU6	CMS final rule on radio-diagnostic reimbursement policy		05/11/24	272.99KB	Share
CU6	Notification regarding unquoted securities - CU6		01/11/24	19.75KB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	7.06MB	Share
CU6	Cleansing Notice		28/10/24	248.77KB	Share
CU6	Application for quotation of securities - CU6		28/10/24	17.53KB	Share
CU6	Notice of Annual General Meeting/Proxy Form		18/10/24	1.35MB	Share
CU6	Cleansing Notice		17/10/24	248.9KB	Share
CU6	Application for quotation of securities - CU6		17/10/24	22.86KB	Share
CU6	Copper-67 SAR-bisPSMA updates	PRICE SENSITIVE	16/10/24	554.2KB	Share
CU6	Positive guidance from the US FDA on Phase III trial	PRICE SENSITIVE	14/10/24	427.24KB	Share
CU6	Michelle Parker Promoted to CEO	PRICE SENSITIVE	14/10/24	180.26KB	Share
CU6	Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA		08/10/24	186.78KB	Share
CU6	Change of Director's Interest Notices - AT CB CR TR MP		04/10/24	327.47KB	Share
CU6	Cleansing Notice		02/10/24	595.56KB	Share
CU6	Application for quotation of securities - CU6		02/10/24	44.59KB	Share
CU6	COBRA study selected as a Top-Rated Oral Presentation		01/10/24	217.89KB	Share
CU6	CORPORATE GOVERNANCE STATEMENT		30/09/24	639.19KB	Share
CU6	Appendix 4G		30/09/24	357.5KB	Share
CU6	Annual Report to shareholders		30/09/24	10.19MB	Share
CU6	Ceasing to be a substantial holder		26/09/24	633.83KB	Share
CU6	Notification regarding unquoted securities - CU6		24/09/24	20.21KB	Share
CU6	Date of Annual General Meeting		23/09/24	431.51KB	Share
CU6	Initial Director's Interest Notice - Parker		20/09/24	518.13KB	Share
CU6	Appointment of Executive Director to Clarity's Board		20/09/24	161.16KB	Share

CU6 Cleansing Notice
09:39		438.68KB	Share
CU6 Ceasing to be a substantial holder
31/07/25		417.54KB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
31/07/25	PRICE SENSITIVE	9.27MB	Share
CU6 Application for quotation of securities - CU6
31/07/25		14.08KB	Share
CU6 Becoming a substantial holder
29/07/25		769.01KB	Share
CU6 Proposed issue of securities - CU6
28/07/25		15.22KB	Share
CU6 Clarity successfully completes $203 million institutional pl
28/07/25	PRICE SENSITIVE	288.81KB	Share
CU6 Change in substantial holding
24/07/25		1.13MB	Share
CU6 Co-PSMA trial recruitment successfully completed
17/07/25	PRICE SENSITIVE	297.47KB	Share
CU6 Notification of cessation of securities - CU6
14/07/25		12.79KB	Share
CU6 Cleansing Notice
04/07/25		248.26KB	Share
CU6 Application for quotation of securities - CU6
04/07/25		15.55KB	Share
CU6 Notice of initial substantial holder
04/07/25		191.69KB	Share
CU6 Change of Director's Interest Notice - M Parker
04/07/25		256.82KB	Share
CU6 Change of Director's Interest Notice - C Biggin
04/07/25		256.88KB	Share
CU6 Change of Director's Interest Notice - A Taylor
04/07/25		257.11KB	Share
CU6 Cleansing Notice
02/07/25		594.79KB	Share
CU6 Application for quotation of securities - CU6
02/07/25		18.79KB	Share
CU6 Change in substantial holding
01/07/25		1.2MB	Share
CU6 Cleansing Notice
24/06/25		248.3KB	Share
CU6 Application for quotation of securities - CU6
24/06/25		18.09KB	Share
CU6 Clarity enters a Commercial Manufacturing Agreement
17/06/25	PRICE SENSITIVE	318.57KB	Share
CU6 SABRE topline results
13/06/25	PRICE SENSITIVE	392.88KB	Share
CU6 DISCO topline results
05/06/25	PRICE SENSITIVE	373.31KB	Share
CU6 Ceasing to be a substantial holder
05/06/25		250.34KB	Share
CU6 Notification regarding unquoted securities - CU6
30/05/25		15.85KB	Share
CU6 First patient imaged in Phase III AMPLIFY trial
29/05/25	PRICE SENSITIVE	328.2KB	Share
CU6 AMPLIFY trial commences
20/05/25	PRICE SENSITIVE	332.81KB	Share
CU6 Ceasing to be a substantial holder
15/05/25		441.44KB	Share
CU6 Becoming a substantial holder
13/05/25		384.07KB	Share
CU6 Change in substantial holding
02/05/25		1.45MB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	8.35MB	Share
CU6 Change in substantial holding
22/04/25		1.36MB	Share
CU6 Ceasing to be a substantial holder
17/04/25		489.99KB	Share
CU6 Clarity signs commercial-scale copper-64 Supply Agreement
17/04/25	PRICE SENSITIVE	241.42KB	Share
CU6 $11.1 million RDTI and refocus on high-priority programs
17/04/25	PRICE SENSITIVE	245.71KB	Share
CU6 Becoming a substantial holder
16/04/25		800.71KB	Share
CU6 First patient treated in the Phase II of the SECuRE trial
15/04/25	PRICE SENSITIVE	333.19KB	Share
CU6 Change of Registered Office and Registry Address
14/04/25		282.98KB	Share
CU6 Becoming a substantial holder
11/04/25		424.61KB	Share
CU6 Notification of cessation of securities - CU6
10/04/25		12.79KB	Share
CU6 Becoming a substantial holder
09/04/25		2.18MB	Share
CU6 Cleansing Notice
05/03/25		248.11KB	Share
CU6 Application for quotation of securities - CU6
05/03/25		17.62KB	Share
CU6 Clarity signs Cu-64 Supply Agreement with UQ
05/03/25	PRICE SENSITIVE	304.33KB	Share
CU6 SECuRE trial update
05/03/25	PRICE SENSITIVE	427.22KB	Share
CU6 Half Yearly Report and Accounts
28/02/25		14.28MB	Share
CU6 Appendix 4D
28/02/25	PRICE SENSITIVE	832.35KB	Share
CU6 Clarity receives US FDA FTD for the treatment of mCRPC
19/02/25	PRICE SENSITIVE	587.09KB	Share
CU6 Response to ASX Cleansing Notice Timing Letter
18/02/25		1.16MB	Share
CU6 Cleansing Notice
11/02/25		247.84KB	Share
CU6 Application for quotation of securities - CU6
11/02/25		22.79KB	Share
CU6 Clarity expands pipeline with Cu-64/67 SAR-trastuzumab
11/02/25	PRICE SENSITIVE	325.31KB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
31/01/25	PRICE SENSITIVE	9.75MB	Share
CU6 Cleansing Notice
29/01/25		170.38KB	Share
CU6 Application for quotation of securities - CU6
29/01/25		25.57KB	Share
CU6 Clarity to present COBRA and CLARIFY abstracts
28/01/25	PRICE SENSITIVE	337.19KB	Share
CU6 Clarity receives U.S. FDA Fast Track Designation
24/01/25	PRICE SENSITIVE	663.71KB	Share
CU6 Cleansing Notice
22/01/25		169.83KB	Share
CU6 Application for quotation of securities - CU6
22/01/25		17.71KB	Share
CU6 Notification of cessation of securities - CU6
08/01/25		14.16KB	Share
CU6 Cleansing Notice
18/12/24		222.15KB	Share
CU6 Application for quotation of securities - CU6
18/12/24		17.75KB	Share
CU6 Novel FAP-targeted radiopharmaceutical
18/12/24	PRICE SENSITIVE	186.57KB	Share
CU6 S&P DJI Announces December 2024 Quarterly Rebalance
06/12/24	PRICE SENSITIVE	81.25KB	Share
CU6 Cleansing Notice
06/12/24		595.39KB	Share
CU6 Application for quotation of securities - CU6
06/12/24		17.75KB	Share
CU6 Last patient assessment completed for SARTATE trial
28/11/24	PRICE SENSITIVE	438.4KB	Share
CU6 First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA
26/11/24	PRICE SENSITIVE	1.74MB	Share
CU6 Change of Director's Interests - All Directors
26/11/24		494.14KB	Share
CU6 Notification regarding unquoted securities - CU6
25/11/24		43.31KB	Share
CU6 Results of Meeting
20/11/24		70.52KB	Share
CU6 Chairperson Address AGM
20/11/24	PRICE SENSITIVE	220.88KB	Share
CU6 AGM MD Presentation
20/11/24	PRICE SENSITIVE	2.69MB	Share
CU6 Head-to-head IIT with SAR-bisPSMA
18/11/24	PRICE SENSITIVE	191.51KB	Share
CU6 Clarity and Nucleus RadioPharma sign MSA
11/11/24	PRICE SENSITIVE	212.65KB	Share
CU6 CMS final rule on radio-diagnostic reimbursement policy
05/11/24		272.99KB	Share
CU6 Notification regarding unquoted securities - CU6
01/11/24		19.75KB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	7.06MB	Share
CU6 Cleansing Notice
28/10/24		248.77KB	Share
CU6 Application for quotation of securities - CU6
28/10/24		17.53KB	Share
CU6 Notice of Annual General Meeting/Proxy Form
18/10/24		1.35MB	Share
CU6 Cleansing Notice
17/10/24		248.9KB	Share
CU6 Application for quotation of securities - CU6
17/10/24		22.86KB	Share
CU6 Copper-67 SAR-bisPSMA updates
16/10/24	PRICE SENSITIVE	554.2KB	Share
CU6 Positive guidance from the US FDA on Phase III trial
14/10/24	PRICE SENSITIVE	427.24KB	Share
CU6 Michelle Parker Promoted to CEO
14/10/24	PRICE SENSITIVE	180.26KB	Share
CU6 Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA
08/10/24		186.78KB	Share
CU6 Change of Director's Interest Notices - AT CB CR TR MP
04/10/24		327.47KB	Share
CU6 Cleansing Notice
02/10/24		595.56KB	Share
CU6 Application for quotation of securities - CU6
02/10/24		44.59KB	Share
CU6 COBRA study selected as a Top-Rated Oral Presentation
01/10/24		217.89KB	Share
CU6 CORPORATE GOVERNANCE STATEMENT
30/09/24		639.19KB	Share
CU6 Appendix 4G
30/09/24		357.5KB	Share
CU6 Annual Report to shareholders
30/09/24		10.19MB	Share
CU6 Ceasing to be a substantial holder
26/09/24		633.83KB	Share
CU6 Notification regarding unquoted securities - CU6
24/09/24		20.21KB	Share
CU6 Date of Annual General Meeting
23/09/24		431.51KB	Share
CU6 Initial Director's Interest Notice - Parker
20/09/24		518.13KB	Share
CU6 Appointment of Executive Director to Clarity's Board
20/09/24		161.16KB	Share

REFRESH

1 2 3 4

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $4.50		Change 0.130(2.97%)		Mkt cap ! $1.699B

Open	High	Low	Value	Volume
$4.37	$4.64	$4.36	$7.313M	1.615M

Buyers (Bids)

No.	Vol.	Price($)
12	13213	$4.50

Sellers (Offers)

Price($)	Vol.	No.
$4.51	1430	8

View Market Depth

No.	Vol.	Price($)
10	8030	4.470
7	16659	4.460
13	34548	4.450
7	17825	4.440
9	14663	4.430

Price($)	Vol.	No.
4.490	5286	16
4.500	9611	9
4.510	10213	9
4.520	21933	11
4.530	8287	6

Last trade - 11.11am 01/08/2025 (20 minute delay)


Last $4.55		Change 0.130 ( 3.86 %)
Open	High	Low	Volume
$4.42	$4.64	$4.36	228764
Last updated 11.30am 01/08/2025 ?

CU6 (ASX) Chart

CLARITY PHARMACEUTICALS LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Codeifai looks to ride AI wave as Quantum Computing becomes a necessity

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

Top Stories